Reclast (Zoledronate) Prevents Fractures in Women With Osteopenia

The old may be new again — at least when it comes to preventing fractures in postmenopausal women with low bone mineral density.

A study was published in the December 20 issue of New England Journal of Medicine Provide evidence that once-every 18-month doses of Reclast (zoledronate), a drug that first gained FDA approval in the early 2000s, may help reduce fracture risk among older women. 65 years or older with osteoporosis, a precursor to osteoporosis, a progressive bone erosion condition that affects an estimated 12 million Americans, according to the International Osteoporosis Foundation (IOF). The IOF estimates that more than 30 million American adults (about 80% of them women) have osteoporosis that likely develops into the most serious form of the condition as they age.

Says Ian R. Reed, one of the study’s authors, and deputy dean of the School of Medical and Health Sciences at the University of Auckland in New Zealand.

“It is a neglected patient group, although it is a very large group. We chose to explore the use of zoledronate because its rarity and proven safety recommended it for use in this low-risk group,” says Dr. Reed.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button